

Product Name: Tankyrase Inhibitors (TNKS) 22
Revision Date: 01/10/2021

### **Product Data Sheet**

# Tankyrase Inhibitors (TNKS) 22

**Cat. No.:** A8600

CAS No.:

In Vitro

Formula: C25H25N5O3S


**M.Wt:** 475.56

Synonyms: TNKS 22;TNKS-22

Target: Chromatin/Epigenetics

Pathway: PARP

Storage: Store at -20°C



## Solvent & Solubility

insoluble in H2O; insoluble in DMSO; ≥3.07 mg/mL in EtOH with gentle warming

**Mass** Solvent 1mg 5mg 10mg Preparing Concentration Stock Solutions 1 mM 2.1028 mL 10.5139 mL 21.0278 mL 2.1028 mL 5 mM 0.4206 mL 4.2056 mL 10 mM 1.0514 mL 2.1028 mL 0.2103 mL1

Please refer to the solubility information to select the appropriate solvent.

## **Biological Activity**

Shortsummary	Tankyrase inhibitor	
IC <sub>50</sub> & Target		
In Vitro	Cell Viability Assay	
	Cell Line:	SW480-TBC cell lines
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining
		a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or
		shake it in the ultrasonic bath for a while. Stock solution can be stored below
		-20°C for several months.
	Reacting conditions:	24 h; IC50=3.7nM

	Applications:	Tankyrase Inhibitors (TNKS) 22, lead-optimized phenyloxadiazole compounds,
		has a good enzymatic potency and cellular potency with IC50 value of 3.7 nM in
		the SW480-TBC cellular assay. The compound demonstrated excellent
		potencies in TNKS2 autoparsylation assay and the two additional functional
		cellular assays.
	Animal experiment	
In Vivo	Animal models:	Athymic nude mice.
	Dosage form:	10 and 50 mg/kg; q.d.; oral taken
	Applications:	Tankyrase Inhibitors (TNKS) 22 was evaluated for Wnt-pathway specific
		pharmacological activity in mouse tumor pharmacodynamic (PD) models.
		Upon once daily oral administration (at 10 and 50 mg/kg) to mice (n=4) bearing
		human DLD-1 tumors for 3 days, both compounds exhibited statistically
		significant, dose-dependent axin2 accumulation (2.7-to 3.5-fold) and inhibition
		of STF (51-58%) at day 3 (24 h after the last dose) .
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may
	OE COURT	slightly differ with the theoretical value. This is caused by an experimental
	And the state of t	system error and it is normal.

### **Product Citations**

See more customer validations on www.apexbt.com.

#### References

[1] Hua Z, Bregman H, Buchanan J L, et al. Development of Novel Dual Binders as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors[J]. Journal of medicinal chemistry, 2013, 56(24): 10003-10015.

A.P.E.I.B.IO

#### Caution

#### FOR RESEARCH PURPOSES ONLY.

#### NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

### **APExBIO Technology**

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com



APE, BIO

APE BIO

APE BIO

APE BIO

APE, BIO

APEVEIO